期刊文献+

左西孟旦治疗失代偿性心力衰竭患者的临床效果观察 被引量:6

Clinical observation of levosimendan in the treatment of patients with decompensated heart failure
在线阅读 下载PDF
导出
摘要 目的针对左西孟旦治疗失代偿性心力衰竭患者的治疗效果进行观察。方法随机选取我院2016年4月~2017年7月收治的失代偿性心力衰竭患者共计44例,根据入院大小号分为研究组和对比组,对比组使用盐酸多巴酚丁胺治疗,研究组使用左西孟旦治疗,对比分析两组患者心功能指标、治疗效果和不良反应发生率。结果研究组患者在SV、BNP、LVEF等心功能指标中均明显优于对比组,组间对比差异有统计学意义(P<0.05);研究组患者治疗总有效率高于对比组、不良反应发生率低于对比组,经统计学对比分析差异有统计学意义(P<0.05)。结论左西孟旦对失代偿性心力衰竭患者的治疗效果较好,安全性较高,具有较高的临床应用价值。 Objective To observe the therapeutic effect of levosimendan on patients with decompensated heart failure.Methods Forty-four patients with decompensated heart failure from April 2016 to July 2017 were randomly selected and divided into study group and contrast group according to the size of admission number.The contrast group was treated with dobutamine hydrochloride,and the study group was treated with levosimendan.The cardiac function index,treatment effect and the incidence of adverse reaction were compared and analyzed in the two groups.Results The SV,BNP and LVEF in the study group were significantly better than those in the contrast group(P<0.05).The total effective rate of treatment in the study group was higher than that in the contrast group and the incidence of adverse reactions was lower than that in the contrast group,and the statistical analysis was significant(P<0.05).
作者 宋岸坚 任强 林雪梅 陈基华 SONG Anjian;REN Qiang;LIN Xuemei;CHEN Jihua(Department of Cardiology,Jiangmen Central Hospital,Guangdong,Jiangmen 529000,China)
出处 《中国医药科学》 2018年第7期251-253,共3页 China Medicine And Pharmacy
关键词 左西孟旦 失代偿性 心力衰竭 效果 Levosimendan Decompensated Heart failure Effect
  • 相关文献

参考文献16

二级参考文献124

  • 1TTiackray S, Easthaugh J, Freeman tie N,et al. The effectiveness andrelative effectiveness of intravenous inotropic drugs acting through theadrenergic pathway in patients with heart failure - a meta - regressionanalysis. Eur J Heart Fail, 2002,4:515-529.
  • 2Earl GL,Fitzpatrick JT. Levosimendan:a novel inotropic agent fortreatment of acute, decompensated heart failure. Ann Pharmacother,2005,39:1888-1896.
  • 3Caimmi PP,Kapetanakis EI^Beggino C,et al. Management of acutecardiac failure by intracoronary administration of levosimendan. JCardiovasc Pharmacol,2011,58:246-253.
  • 4Aidonidis G,Kanonidis I,Koutsimanis V,et al. Efficiency and safetyof prolonged levosimendan infusion in patients with acute heart fail -ure. Cardiol Res Pract,2011,34: 2302.
  • 5Kivikko M,Lehtonen L. Levosimendan:a new inodilatory drug for thetreatment of decompensated heart failure. Curr Pharm Des,2005,11:435-455.
  • 6Morelli A, Teboul JL. Effects of levosimeudan on systemic and regional hemodynamics in septic myocardial depression[J]. Intensive Care Med, 2006,32 (5) : 791 - 792.
  • 7Egan JR, Clarke AJ, Wiluams S, et al. Levosimendan for lowcardia coutputape diatfice experience[J]. Intensive Care Med, 2006,21 (3): 183 - 187.
  • 8Rognoni A, Lupi A, Lazzero M. Levosimendan: from basic science to clinical trials [ J ]. Recent Pat Cardiovasc Drug Discov, 2011,5 (2) : 315 - 316.
  • 9Nieminen MS,Bohm M,Cowie MR,et al.Executive summary of theguidelines on the diagnosis and treatment of acute heart failure:theTask Force on Acute Heart Failure of the European Societ y ofCardiology[J],Eur Heart J,2005,26(4):384-416.
  • 10Follath F,Cleland JG,Just H,et al.Efficacy and safety ofintravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study ):a randomised double-blindtrial[J].Lancet,2002,360(9328):196-202.

共引文献209

同被引文献59

引证文献6

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部